Awakn Life Sciences Corp. (AWKN.NE)
Chart Events
Performance Outlook
| Previous Close | 1.9800 |
| Open | 2.0400 |
| Bid | 1.9300 x N/A |
| Ask | 2.0000 x N/A |
| Day's Range | 1.9800 - 2.0400 |
| 52 Week Range | 1.5000 - 2.5000 |
| Volume | 60,166 |
| Avg. Volume | 17,076 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- CNW Group
KCSA Psychedelics Virtual Investor Conference Agenda Announced for October 13th & 14th
Virtual Investor Conferences in partnership with KCSA Strategic Communications today announced the agenda for the upcoming KCSA Psychedelics Virtual Investor Conference. Individual investors, institutional investors, advisors, and analysts are invited to attend the two-day program beginning Wednesday, October 13, 2021, at 9:45 a.m. ET.
- Newsfile
Awakn Life Sciences to Present at the KCSA Psychedelics Virtual Investor Conference on October 13th
Toronto, Ontario--(Newsfile Corp. - October 8, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat Addiction, announced today that Anthony Tennyson, CEO of Awakn Life Sciences, will participate in the KCSA Psychedelics Investor Conference to be held at VirtualInvestorConferences.com on October 13-14, 2021. Anthony Tennyson will present live on Wednesday, Oc
- Newsfile
Awakn Life Sciences Announces Closing of Acquisition of Leading Ketamine-Assisted Psychotherapy Clinic in Norway
Transaction concludes with the launch of "Awakn Clinics Oslo AS" as part of Awakn Life Sciences Nordic Expansion Toronto, Ontario--(Newsfile Corp. - October 5, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat addiction, is pleased to announce the closing of its acquisition of Axonklinikken AS ("Axon"), a leading ketamine-assisted psychot
